Juan Pablo Díaz-Sánchez

Juan Pablo Díaz-Sánchez

Auto-generated profile, based on publicly available information

Juan Pablo Díaz-Sánchez

Research Division, Instituto Nacional de Geriatría

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
DRDaniel Ramírez‐García
Daniel Ramírez‐García
JPJerónimo Perezalonso‐Espinosa
Jerónimo Perezalonso‐Espinosa
PMPadme Nailea Méndez‐Labra
Padme Nailea Méndez‐Labra
CFCarlos A. Fermín‐Martínez
Carlos A. Fermín‐Martínez
JDJuan Pablo Díaz‐Sánchez
Juan Pablo Díaz‐Sánchez
OBOmar Yaxmehen Bello‐Chavolla
Omar Yaxmehen Bello‐Chavolla
Background: Effective cardiovascular disease (CVD) risk management is essential for optimal diabetes care. Here, we estimated the prevalence and determinants of CVD risk factor control among individuals with diagnosed diabetes in Mexico. Methods: We analyzed data from individuals ≥20 years with diagnosed diabetes from 2016 to 2023 Mexican National Health and Nutrition Surveys. We estimated the prevalence of glycemic, blood pressure, noncurrent smoking, low‐density lipoprotein cholesterol, and combined CVD risk factor control. We estimated use of blood pressure‐lowering, cholesterol‐lowering, and glucose‐lowering medication and explored determinants of control achievement using logistic regression. Results: We analyzed data from 2916 participants, representing 43.2 million adults with diagnosed diabetes during 2016 to 2023. In 2023, glycemic control was 29% (95% CI, 21%–38%), blood pressure control 22.9% (95% CI, 14%–31%), and noncurrent smoking 89% (95% CI, 81%–96%). The prevalence of high or very‐high CVD risk using Systematic Coronary Risk Evaluation 2‐Diabetes increased from 59.8% (95% CI, 52.1%–67.0%) in 2016 to 68.4% (95% CI, 55.6%–78.9%) in 2023, representing ~5.1 million adults. Low‐density lipoprotein cholesterol control increased from 2.8% (95% CI, 1.2%–4.4%) in 2016 to 6.6% (95% CI, 1.9%–11.2%) in 2023 and statin use from 5.5% in 2016 to 63% in 2023. Combined risk factor control achievement was low due to suboptimal low‐density lipoprotein cholesterol control and was more likely achieved in women, younger individuals, and those with college education or living in states with higher socioeconomic position. Conclusions: Despite increasing CVD risk during this period, glycemic and CVD risk factor management for adults with diabetes in Mexico remains suboptimal. Our findings suggest a need for strategies to improve CVD risk management to reduce diabetes‐related mortality and complications.

9 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
DRDaniel Ramírez-García
Daniel Ramírez-García
JDJuan Pablo Díaz-Sánchez
Juan Pablo Díaz-Sánchez
KCKarime Berenice Carrillo-Herrera
Karime Berenice Carrillo-Herrera
LCLeslie Alitzel Cabrera-Quintana
Leslie Alitzel Cabrera-Quintana
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
BACKGROUND Cardiovascular disease (CVD) is the leading cause of mortality in Latin America, yet most CVD risk prediction models were developed in high-income countries with limited validations in these settings. OBJECTIVES To externally validate CVD risk prediction models for 10-year fatal CVD, and recalibrate the Globorisk-fatal model in Mexican population. METHODS We analyzed 112,262 adults ≥40 years from the Mexico City Prospective Study. Outcomes were restricted to fatal CVD, including myocardial infarction (MI) and stroke, censored at 10 years. CVD risk was estimated using the laboratory- and office-based Framingham, Globorisk, Globorisk-LAC, WHO, and SCORE2 equations. Discrimination was assessed with Harrell’s c-statistic and AUROCs, calibration with mean estimates, slopes, and calibration curves, and overall performance with Brier scores. Sex-specific recalibration of the Globorisk-fatal model was performed using observed 10-year risks. RESULTS During 10 years of follow-up, 2,429 fatal CVD events were recorded (1,667 MI, 762 stroke). All models showed good discrimination, with c-statistics ranging from 0.761-0.805 in men and 0.797-0.831 in women. The Globorisk-fatal model had the highest c-statistic in women (0.831, 95%CI 0.821-0.841), and the laboratory-based WHO-MI model in men (0.805, 95%CI 0.783-0.827). Despite this, all equations consistently overestimated CVD risk, particularly in women. Calibration analyses revealed systematic overprediction at higher risk levels, more pronounced in men. Recalibration of the Globorisk-fatal model improved agreement between predicted and observed risks, reducing overestimation. CONCLUSIONS CVD risk models showed good discrimination but consistently overestimated risk in this Mexican cohort. The recalibrated Globorisk-fatal model improves risk estimation of fatal CVD in Mexican adults.

16 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
JDJuan Pablo Díaz-Sánchez
Juan Pablo Díaz-Sánchez
DGDaniel Ramírez- García
Daniel Ramírez- García
KCKarime Berenice Carrillo-Herrera
Karime Berenice Carrillo-Herrera
LCLeslie Alitzel Cabrera-Quintana
Leslie Alitzel Cabrera-Quintana
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
BACKGROUND: Cardiovascular disease (CVD) is a leading cause of diabetes-related mortality in Mexico. Although diabetes subgroups capture underlying disease heterogeneity, their association and utility for risk prediction for fatal CVD in Mexican adults remain unclear. METHODS: We analyzed 24,943 adults with diabetes from the Mexico City Prospective Study. Participants were classified into mild obesity-related (MOD), severe insulin-deficient (SIDD), severe insulin-resistant (SIRD), and mild age-related (MARD) diabetes using a self-normalizing neural network algorithm. Fatal CVD was defined as death from ischemic heart disease or stroke (ICD-10 I20–I25, I60–I69). SCORE2-Diabetes was recalibrated and validated overall and by diabetes subgroup. Cox proportional hazards models were used to estimate subgroup-specific risk, and sequential models evaluated the incremental predictive value of diabetes subgroups combined with SCORE2-Diabetes and traditional risk factors. RESULTS: Over a median follow-up of 19.3 years (IQR 12.7-20.6), 2,223 fatal CVD events (8.9%) were recorded. SIDD was the most prevalent subgroup (50.6%), followed by SIRD (17.3%), MARD (16.8%), and MOD (15.4%). SIDD and MARD showed the highest adjusted risk of fatal CVD (RR 1.58 [95%CI 1.38–1.81] and 1.35 [1.13–1.60]), whereas MOD and SIRD had lower risk. Recalibrated SCORE2-Diabetes demonstrated adequate discrimination overall (c-statistic 0.759, 95%CI 0.745-0.773) and for most subgroups but underperformed in MARD, with recalibration improving risk assessment. The combination of diabetes subgroups and SCORE2-Diabetes improved prediction for fatal CVD outcomes. CONCLUSIONS: Diabetes subgroups show heterogeneity in fatal CVD risk in Mexican adults. SIDD and MARD identify high-risk individuals and integration subgroup classification with SCORE2-Diabetes enhances risk prediction.

17 April 2023 in medRxiv
Verified
Preprint
Open access
PDF file
AVArsenio Vargas-Vázquez
Arsenio Vargas-Vázquez
CFCarlos Alberto Fermín-Martínez
Carlos Alberto Fermín-Martínez
NANeftali Eduardo Antonio-Villa
Neftali Eduardo Antonio-Villa
LFLuisa Fernández-Chirino
Luisa Fernández-Chirino
DRDaniel Ramírez-García
Daniel Ramírez-García
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
BACKGROUND: Remnant cholesterol (RC) and insulin resistance (IR) have been independently associated with cardiovascular risk. OBJECTIVES: We evaluated the mediating role of IR in the risk conferred by RC on atherosclerotic cardiovascular disease (ASCVD) mortality. METHODS: Analysis of the National Health and Nutrition Examination Survey (NHANES-III/IV), including 16,201 individuals ≥20 years without diabetes and with complete mortality data. RC levels were calculated using total cholesterol, non-HDL-c, and LDL-c estimated with Sampson’s formula; IR was defined as HOMA2-IR≥2.5 and ASCVD mortality as a composite of cardiovascular and cerebrovascular mortality. Multiple linear regression was used to assess the relationship between HOMA2-IR and RC and competing-risk models to assess their joint role in ASCVD mortality. Causally ordered mediation models were used to explore the mediating role of IR in RC-associated ASCVD mortality. RESULTS: We identified an association between higher HOMA2-IR and higher RC levels. The effect of IR on ASCVD mortality was predominant (sHR 1.68, 95%CI 1.42-1.98) and decreased at older ages (sHR 0.993, 95%CI 0.991-0.995) compared to RC (sHR 0.965, 95%CI 0.826-1.126). Higher risk of ASCVD mortality was observed in individuals with IR but normal RC (sHR 1.19, 95%CI 1.01-1.41) and subjects with IR and high RC (sHR 1.27, 95%CI 1.07-1.50), but not in subjects without IR but high RC. In mediation models, HOMA2-IR accounted for 86.5% (95%CI 78.8-100.0) of the effect of RC levels on ASCVD mortality. CONCLUSIONS: Our findings suggest that RC potentiates the risk of ASCVD mortality through its effect on whole-body insulin sensitivity, particularly among younger individuals. CONDENSED This study aimed to assess the role of insulin resistance (IR) in the association between remnant cholesterol (RC) and atherosclerotic cardiovascular disease (ASCVD) mortality. Using data from NHANES-III/IV, the study found that the effect of IR on ASCVD mortality was predominant compared to RC. Individuals with IR but normal RC or IR with elevated RC had higher risk of ASCVD mortality compared to subjects with elevated RC without IR. Overall, IR accounted for 86.5% of the effect of RC on ASCVD mortality. RC increases the risk of ASCVD mortality through its effect on insulin sensitivity, particularly among younger individuals. PERSPECTIVES: COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS: In patients with elevated remnant cholesterol, insulin resistance potentiates its effect on atherosclerotic cardiovascular disease mortality. TRANSLATIONAL OUTLOOK: Additional research from randomized clinical trials is needed to evaluate whether concomitant therapies to improve insulin sensitivity in patients with residual cardiovascular risk may provide an additional benefit in reducing cardiovascular disease burden and mortality. GRAPHICAL ABSTRACT – CENTRAL IMAGE:

24 April 2026 in medRxiv
Verified
Preprint
Open access
PDF file
AMAndrea Malagon-Liceaga
Andrea Malagon-Liceaga
MBMartín Roberto Basile-Alvarez
Martín Roberto Basile-Alvarez
CFCarlos A. Fermín-Martínez
Carlos A. Fermín-Martínez
DRDiana Laura Ramírez-Rivera
Diana Laura Ramírez-Rivera
JPJerónimo Perezalonso-Espinosa
Jerónimo Perezalonso-Espinosa
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Background: Prediabetes is highly prevalent in older adults and is characterized by heterogeneous clinical trajectories, including regression to normoglycemia and progression to diabetes. While prediabetes has been associated with impaired physical function and frailty, the longitudinal impact of both a single diagnosis and dynamic glycemic transitions on functional outcomes remains unclear. We aimed to evaluate associations between baseline prediabetes and glycemic transitions over time with trajectories of functional capacity and frailty in older adults. Methods: We conducted a pooled analysis of harmonized data from five nationally representative longitudinal aging cohorts (MHAS, HRS, CHARLS, ELSA, CRELES) within the Gateway to Global Aging Data, including adults aged ≥50 years with ≥1 HbA1c measurements. Prediabetes was defined per ADA criteria (HbA1c 5.7-6.4%). Functional outcomes included activities of daily living (ADL), instrumental ADL (IADL), and frailty assessed using Fried phenotype, FRAIL scale, and a deficit-accumulation Frailty Index (FI). Mixed-effects Poisson models estimated incidence rate ratios (IRRs) for baseline prediabetes, while generalized estimating equations assessed time-varying glycemic status and transition trajectories. Models were adjusted for age, sex, cohort, and time-varying covariates, with sensitivity analyses including BMI, smoking, and alcohol intake. Findings: Among 18,571 participants (median follow-up 13.6 years), baseline prediabetes was associated with increased progression of functional deficits and frailty compared with normoglycemia, including higher FI values and accelerated FI progression. Prediabetes was associated with higher incidence of ADL, IADL, and multimorbidity deficits from early follow-up, although time-dependent changes in incidence rates were not significant. In time-varying analyses (n=7,840), both prediabetes and diabetes were associated with higher incidence of functional deficits compared with normoglycemia, with diabetes showing the strongest effects across all outcomes. Diabetes was associated with greater FI burden and accelerated progression, whereas prediabetes showed a smaller increase, with attenuation over time. Among individuals with baseline prediabetes, regression to normoglycemia occurred in 20.8% and was associated with increased incidence of ADL and frailty deficits. In contrast, progression to diabetes occurred in 24.3%, and was associated with lower risk of incident ADL and Fried frailty deficits compared to stable prediabetes. Interpretation: Prediabetes is associated with increased risk of functional decline, frailty, and deficit accumulation in older adults, independent of progression to diabetes. Regression to normoglycemia was associated with higher risk of functional deterioration. These findings suggest that prediabetes reflects a state of metabolic vulnerability linked to biological aging rather than solely a precursor to diabetes and highlights a need to reframe its clinical significance in older populations. Funding: This research was supported by Instituto Nacional de Geriatría in Mexico. RESEARCH IN CONTEXT: Evidence before this study: We searched PubMed up to April 1, 2026, using the terms (“prediabetes”) AND (“frailty” OR “functional decline” OR “activities of daily living” OR “mortality”) AND (“older adults” OR “aging” OR “longitudinal” OR “cohort”). Existing evidence from predominantly single-country and cross-sectional studies suggests that prediabetes is associated with increased risk of frailty, disability, and adverse health outcomes in older adults. However, findings have been inconsistent, particularly regarding incident versus prevalent outcomes and the role of competing risks in aging populations. Importantly, few studies have used harmonized multinational longitudinal data, incorporated repeated measures of glycemic status, or evaluated multiple complementary frailty constructs. The impact of dynamic glycemic transitions, including regression to normoglycemia and progression to diabetes, on functional trajectories remains poorly understood. Added value of this study: This study leverages harmonized longitudinal data from five nationally representative aging cohorts from Mexico, England, China, Costa Rica and the United States to examine both baseline prediabetes and time-varying glycemic status in relation to trajectories of functional decline and frailty. By integrating multiple validated measures of functional capacity and frailty, and applying longitudinal modeling strategies, we provide a comprehensive assessment of the relationship between prediabetes and age-related outcomes. We further characterize glycemic transition trajectories and show that regression to normoglycemia among older adults with prediabetes is associated with increased risk of frailty, while progression to diabetes does not uniformly confer additional risk beyond stable prediabetes. Implications of all the available evidence: Our results support a reconceptualization of prediabetes in older adults as a marker of systemic vulnerability rather than solely a precursor to diabetes. Glycemic status in later life appears to also reflect underlying physiological reserve, with dynamic changes potentially signaling deterioration rather than improvement. Our findings suggest a need to incorporate glycemic markers into geriatric risk stratification and to interpret their changes in the context of aging biology. Future research should focus on elucidating the mechanisms linking dysglycemia with frailty and functional decline, including the roles of sarcopenia, inflammation, and multimorbidity, and on evaluating interventions tailored to older populations across diverse global contexts.

23 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DRDaniel Ramírez-García
Daniel Ramírez-García
CFCarlos A. Fermín-Martínez
Carlos A. Fermín-Martínez
PCPaulina Sánchez Castro
Paulina Sánchez Castro
BCBrenda Guadalupe Cortez-Flores
Brenda Guadalupe Cortez-Flores
JEJerónimo Perezalonso Espinosa
Jerónimo Perezalonso Espinosa
OBOmar Yaxmehen Bello-Chavolla
Omar Yaxmehen Bello-Chavolla
Accurate estimation of glomerular filtration rate (eGFR) is essential for identifying and managing chronic kidney disease (CKD). The CKD-EPI 2021 equation removed the race coefficient from the 2009 version, but its impact in Mexican populations remains unclear. Here, we compared eGFR category prevalence, and predictive performance between the CKD-EPI 2009 and 2021 creatinine-based eGFR equations, as well as the prognostic relevance of reclassification in eGFR categories using the 2021 equation in Mexicans. We evaluated 25,110 adults ≥ 20 years from the 2016-2023 cycles of the Mexican National Health and Nutrition Survey (ENSANUT) to estimate national low eGFR and eGFR category prevalence using both equations. We also assessed 5-year and 10-year risk of all-cause, cardiovascular, and kidney-related mortality in 142,884 adults from the Mexico City Prospective Study (MCPS) using Cox proportional hazards and Fine & Gray regression models. In ENSANUT 2023, prevalence of eGFR <60mL/min/1.73m2 was lower with CKD-EPI 2021 (2.9%, 95%CI 1.56–4.24%) compared to the 2009 equation (3.6%, 95%CI 1.99–5.21). Use of the 2021 equation resulted in upward eGFR reclassification in 6.52% (95%CI 4.07-8.97) of adults ≥ 20 years, particularly among older adults and those with hypertension or diabetes, yielding a reduction in 486,532 adults identified with eGFR <60mL/min/1.73m 2 compared to the 2009 equation. In MCPS, despite both equations showing similar C-statistics, the 2021 equation showed slightly improved predictive performance for 5-year and 10-year mortality outcomes. The 2021 equation reclassified 8.3% of participants to higher eGFR categories, and reclassification was associated with decreased risk of all-cause, cardiovascular, and kidney-related mortality, particularly for participants reclassified upward from G3a-G5 categories. The CKD-EPI 2021 equation yields lower prevalence of low eGFR but leads to prognostically relevant eGFR category reclassification compared to the 2009 equation. Our findings support the implementation of the 2021 equation for population health monitoring in Mexico without compromising prognostic utility.